Bank of America Securities issued a research report stating that MICROPORT (00853) recorded total revenue of $1.105 billion in 2025. Excluding foreign exchange factors, revenue increased by 6% year-on-year, meeting the firm's expectations. The report also noted that the group's GloMatrix global commercialization platform has achieved breakeven and has become a core growth engine for the company, driving revenue to increase by 78.8% year-on-year to $16.39 million in the 2025 fiscal year, excluding foreign exchange impacts. Due to improvements in the asset-liability structure, the firm has lowered its forecast for MICROPORT's financing costs. It has reduced the target price from HK$17 to HK$13.9, while reiterating a "Buy" rating, citing strong growth potential from the company's overseas markets and surgical robotics business. To reflect that MicroPort Brain Science (02172) is no longer included in the consolidated financial statements, Bank of America Securities has lowered its revenue forecasts for MICROPORT for 2026 to 2028 by 10.9%, 11.7%, and 12.9%, respectively. Concurrently, considering improvements in the product mix, the firm has raised its gross margin forecasts for 2026 to 2028 by 1.9 to 2.1 percentage points. Based on increased costs due to overseas business expansion, the firm has also raised its forecast for the operating expense ratio by 11.5 to 12.6 percentage points.